Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab169289-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $39.90 | |
| Ab169289-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $177.90 | |
| Ab169289-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $537.90 | |
| Ab169289-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $867.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Siltuximab (anti-IL-6) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-6, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Interleukin BSF 2 antibody; B cell differentiation factor antibody; B cell stimulatory factor 2 antibody; B-cell stimulatory factor 2 antibody; BSF 2 antibody; BSF-2 antibody; BSF2 antibody; CDF antibody; CTL differentiation factor antibody; Cytotoxic T c |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | IL-6 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTAGONIST |
| Mechanism of action | ANTAGONIST of Interleukin-6 inhibitor |
| Product Description | Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 144.98 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 541502-14-1 |
Siltuximab (anti-IL-6) (Ab169289)- ELISA
Immobilized Recombinant Human IL-6 Protein (rp147615) at 1 μg/mL can bind Siltuximab (anti-IL-6) (Ab169289) with the EC₅₀ of 47.28 ng/mL.
Siltuximab (anti-IL-6) (Ab169289) - SEC
The purity of Siltuximab (anti-IL-6) (Ab169289) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Wikipedia | Siltuximab |
|---|---|
| IMGT/mAb-DB | 297 |
| Immunopaedia Search | siltuximab |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F0900978 | Certificate of Analysis | Sep 06, 2023 | Ab169289 |
| ZJ23F0900979 | Certificate of Analysis | Sep 06, 2023 | Ab169289 |
| 1. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al.. (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.. J Clin Oncol, 28 (23): (3701-8). [PMID:20625121] |
| 2. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T et al.. (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.. Blood, 74 (4): (1360-7). [PMID:2788466] |
| 3. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] |
| 4. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014) Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.. MAbs, 6 (3): (774-82). [PMID:24670876] |
| 5. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] |
| 6. Q Y Chen. (1992-09-01) [Stable and efficient expression of human interleukin-6 cDNA in mammalian cells after gene transfer].. Zhonghua zhong liu za zhi [Chinese journal of oncology], 14 ((5)): (340-344). [PMID:1291290] |
| 7. H C van Zaanen,R P Koopmans,L A Aarden,H J Rensink,J M Stouthard,S O Warnaar,H M Lokhorst,M H van Oers. (1996-09-15) Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.. The Journal of clinical investigation, 98 ((6)): (1441-1448). [PMID:8823310] |
| 8. Kim D, Won HY, Hwang ES, Kim YK, Choo HP.. (2017) Synthesis of benzoxazole derivatives as interleukin-6 antagonists.. Bioorg Med Chem, 25 (12): (3127-3134). [PMID:28442260] |
| 9. May, L T LT, Shaw, J E JE, Khanna, A K AK, Zabriskie, J B JB and Sehgal, P B PB.. (1991) Marked cell-type-specific differences in glycosylation of human interleukin-6.. Cytokine, [PMID:1883960] |
| 10. Lütticken, C C, Krüttgen, A A, Möller, C C, Heinrich, P C PC and Rose-John, S S.. (1991) Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6.. FEBS letters, (6): [PMID:2037043] |
| 11. Clogston, C L CL, Boone, T C TC, Crandall, B C BC, Mendiaz, E A EA and Lu, H S HS.. (1989) Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor.. Archives of biochemistry and biophysics, [PMID:2472117] |
| 12. Ming, J E JE, Cernetti, C C, Steinman, R M RM and Granelli-Piperno, A A.. (1989) Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium.. The Journal of molecular and cellular immunology : JMCI, [PMID:2610854] |
| 13. Tonouchi, N N, Miwa, K K, Karasuyama, H H and Matsui, H H.. (1989) Deletion of 3' untranslated region of human BSF-2 mRNA causes stabilization of the mRNA and high-level expression in mouse NIH3T3 cells.. Biochemical and biophysical research communications, (15): [PMID:2789513] |
| 14. Zilberstein, A A, Ruggieri, R R, Korn, J H JH and Revel, M M.. (1986) Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.. The EMBO journal, [PMID:3023045] |
| 15. Wong, G G GG, Witek-Giannotti, J J, Hewick, R M RM, Clark, S C SC and Ogawa, M M.. (1988) Interleukin 6: identification as a hematopoietic colony-stimulating factor.. Behring Institute Mitteilungen, [PMID:3266463] |
| 16. Van Damme, J J and 5 more authors.. (1988) Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:3279116] |
| 17. Brakenhoff, J P JP, de Groot, E R ER, Evers, R F RF, Pannekoek, H H and Aarden, L A LA.. (1987) Molecular cloning and expression of hybridoma growth factor in Escherichia coli.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:3320204] |
| 18. Hirano, T T and 9 more authors.. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.. Nature, [PMID:3491322] |
| 19. Yasukawa, K K and 6 more authors.. (1987) Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene.. The EMBO journal, [PMID:3500852] |
| 20. May, L T LT, Helfgott, D C DC and Sehgal, P B PB.. (1986) Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3538015] |
| 21. Haegeman, G G and 5 more authors.. (1986) Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts.. European journal of biochemistry, (15): [PMID:3758081] |
| 22. Breton, J J and 8 more authors.. (1995) Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond.. European journal of biochemistry, (15): [PMID:7851440] |
| 23. Nishimura, C C, Watanabe, A A, Gouda, H H, Shimada, I I and Arata, Y Y.. (1996) Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy.. Biochemistry, (9): [PMID:8555185] |
| 24. Somers, W W, Stahl, M M and Seehra, J S JS.. (1997) 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling.. The EMBO journal, (3): [PMID:9118960] |
| 25. Xu, G Y GY and 6 more authors.. (1997) Solution structure of recombinant human interleukin-6.. Journal of molecular biology, (2): [PMID:9159484] |
| 26. Fishman, D D and 6 more authors.. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.. The Journal of clinical investigation, (1): [PMID:9769329] |
| 27. Foster, C B CB and 11 more authors.. (2000) An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus.. Blood, (1): [PMID:11001912] |
| 28. Ota, N N and 8 more authors.. (2001) A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density.. Journal of human genetics, [PMID:11355017] |
| 29. Chung, Hye Won HW and 8 more authors.. (2003) Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women.. Journal of human genetics, [PMID:12768442] |
| 30. Nemeth, Elizabeta E and 6 more authors.. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.. The Journal of clinical investigation, [PMID:15124018] |
| 31. Wolsk, Emil E, Mygind, Helene H, Grøndahl, Thomas S TS, Pedersen, Bente K BK and van Hall, Gerrit G.. (2010) IL-6 selectively stimulates fat metabolism in human skeletal muscle.. American journal of physiology. Endocrinology and metabolism, [PMID:20823453] |
| 32. Ellingsgaard, Helga H and 20 more authors.. (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.. Nature medicine, (30): [PMID:22037645] |
| 33. Taniguchi, Koji K and 17 more authors.. (2015) A gp130-Src-YAP module links inflammation to epithelial regeneration.. Nature, (5): [PMID:25731159] |
| 34. Tagliabracci, Vincent S VS and 14 more authors.. (2015) A Single Kinase Generates the Majority of the Secreted Phosphoproteome.. Cell, (18): [PMID:26091039] |
| 35. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003] |
